questionsmedicales.fr
Disciplines des sciences naturelles
Science
Recherche
Recherche biomédicale
Expérimentation humaine
Expérimentation humaine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Essais cliniques
Sécurité des patients
Tests diagnostiques
Imagerie médicale
Effets indésirables
Surveillance des patients
Groupes témoins
Essais contrôlés
Critères d'inclusion
Sélection des participants
Symptômes
5
Symptômes
Réactions indésirables
Effets indésirables
Signalement des événements
Variabilité des symptômes
Groupes de traitement
Évaluation des symptômes
Questionnaires
Prévention
5
Prévention des effets indésirables
Surveillance des participants
Consentement éclairé
Évaluation des risques
Information des participants
Consentement éclairé
Recommandations pour les participants
Instructions d'étude
Évaluation de la prévention
Analyses de données
Traitements
5
Médicaments expérimentaux
Thérapies
Administration de médicaments
Voies d'administration
Traitement de contrôle
Comparaison des traitements
Efficacité des traitements
Mesures cliniques
Médecine personnalisée
Profilage génétique
Complications
5
Complications
Réactions allergiques
Gestion des complications
Soins médicaux
Documentation des complications
Rapports d'étude
Prévention des complications
Suivi des participants
Conséquences des complications
Arrêt d'essai
Facteurs de risque
5
Facteurs de risque
Antécédents médicaux
Évaluation des risques
Questionnaires médicaux
Variabilité des risques
Traitements
Minimisation des risques
Sélection des participants
Communication des risques
Consentement éclairé
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Expérimentation humaine : Questions médicales les plus fréquentes",
"headline": "Expérimentation humaine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Expérimentation humaine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Recherche biomédicale",
"url": "https://questionsmedicales.fr/mesh/D035843",
"about": {
"@type": "MedicalCondition",
"name": "Recherche biomédicale",
"code": {
"@type": "MedicalCode",
"code": "D035843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Expérimentation sur soi-même",
"alternateName": "Autoexperimentation",
"url": "https://questionsmedicales.fr/mesh/D032762",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation sur soi-même",
"code": {
"@type": "MedicalCode",
"code": "D032762",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Expérimentation humaine non thérapeutique",
"alternateName": "Nontherapeutic Human Experimentation",
"url": "https://questionsmedicales.fr/mesh/D033281",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine non thérapeutique",
"code": {
"@type": "MedicalCode",
"code": "D033281",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Expérimentation thérapeutique humaine",
"alternateName": "Therapeutic Human Experimentation",
"url": "https://questionsmedicales.fr/mesh/D036302",
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation thérapeutique humaine",
"code": {
"@type": "MedicalCode",
"code": "D036302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.770.644.145.365.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Expérimentation humaine",
"alternateName": "Human Experimentation",
"code": {
"@type": "MedicalCode",
"code": "D006805",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Peter Pickkers",
"url": "https://questionsmedicales.fr/author/Peter%20Pickkers",
"affiliation": {
"@type": "Organization",
"name": "Dept. of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: peter.pickkers@radboudumc.nl."
}
},
{
"@type": "Person",
"name": "Paul R Chapman",
"url": "https://questionsmedicales.fr/author/Paul%20R%20Chapman",
"affiliation": {
"@type": "Organization",
"name": "Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia."
}
},
{
"@type": "Person",
"name": "Paul Giacomin",
"url": "https://questionsmedicales.fr/author/Paul%20Giacomin",
"affiliation": {
"@type": "Organization",
"name": "Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia."
}
},
{
"@type": "Person",
"name": "Alex Loukas",
"url": "https://questionsmedicales.fr/author/Alex%20Loukas",
"affiliation": {
"@type": "Organization",
"name": "Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia."
}
},
{
"@type": "Person",
"name": "James S McCarthy",
"url": "https://questionsmedicales.fr/author/James%20S%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Nutrition for Cancer Survivors.",
"datePublished": "2022-10-01",
"url": "https://questionsmedicales.fr/article/36235745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/nu14194093"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hypertension in Cancer Survivors.",
"datePublished": "2022-07-19",
"url": "https://questionsmedicales.fr/article/35852781",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11906-022-01208-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Survival of cancer survivors with a new pancreatic cancer diagnosis.",
"datePublished": "2022-06-08",
"url": "https://questionsmedicales.fr/article/35674139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.4903"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sleep disturbances among cancer survivors.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37837808",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.canep.2023.102471"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychological and sexual problems of cancer survivors.",
"datePublished": "2023-05-30",
"url": "https://questionsmedicales.fr/article/37254933",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4081/aiua.2023.11473"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Disciplines des sciences naturelles",
"item": "https://questionsmedicales.fr/mesh/D010811"
},
{
"@type": "ListItem",
"position": 3,
"name": "Science",
"item": "https://questionsmedicales.fr/mesh/D012586"
},
{
"@type": "ListItem",
"position": 4,
"name": "Recherche",
"item": "https://questionsmedicales.fr/mesh/D012106"
},
{
"@type": "ListItem",
"position": 5,
"name": "Recherche biomédicale",
"item": "https://questionsmedicales.fr/mesh/D035843"
},
{
"@type": "ListItem",
"position": 6,
"name": "Expérimentation humaine",
"item": "https://questionsmedicales.fr/mesh/D006805"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Expérimentation humaine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Expérimentation humaine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Expérimentation humaine",
"description": "Comment évaluer la sécurité d'un essai clinique ?\nQuels tests sont utilisés pour les essais cliniques ?\nComment identifier les effets secondaires ?\nQu'est-ce qu'un groupe témoin ?\nComment sont définis les critères d'inclusion ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Expérimentation humaine",
"description": "Quels symptômes surveiller lors d'un essai ?\nComment signaler un effet indésirable ?\nLes symptômes peuvent-ils varier selon les groupes ?\nQuels sont les symptômes courants des essais ?\nComment évaluer l'impact des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Expérimentation humaine",
"description": "Comment prévenir les effets indésirables ?\nQuelles sont les mesures de sécurité en essais ?\nComment informer les participants des risques ?\nQuelles sont les recommandations pour les participants ?\nComment évaluer la prévention dans les essais ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Expérimentation humaine",
"description": "Quels types de traitements sont testés ?\nComment sont administrés les traitements ?\nQu'est-ce qu'un traitement de contrôle ?\nComment évaluer l'efficacité d'un traitement ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Expérimentation humaine",
"description": "Quelles complications peuvent survenir ?\nComment gérer les complications pendant un essai ?\nLes complications sont-elles documentées ?\nComment prévenir les complications graves ?\nQuelles sont les conséquences des complications ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Expérimentation humaine",
"description": "Quels sont les facteurs de risque pour les essais ?\nComment évaluer les facteurs de risque ?\nLes facteurs de risque varient-ils selon les traitements ?\nComment minimiser les facteurs de risque ?\nLes facteurs de risque sont-ils communiqués aux participants ?",
"url": "https://questionsmedicales.fr/mesh/D006805?mesh_terms=Cancer+Survivors#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la sécurité d'un essai clinique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sécurité est évaluée par des comités d'éthique et des protocoles rigoureux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les essais cliniques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques, biologiques et d'imagerie sont utilisés pour évaluer les effets."
}
},
{
"@type": "Question",
"name": "Comment identifier les effets secondaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont identifiés par la surveillance des participants et des rapports."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un groupe témoin ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est un groupe de participants qui ne reçoit pas le traitement testé."
}
},
{
"@type": "Question",
"name": "Comment sont définis les critères d'inclusion ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères d'inclusion sont définis par des caractéristiques spécifiques des participants."
}
},
{
"@type": "Question",
"name": "Quels symptômes surveiller lors d'un essai ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes à surveiller incluent la douleur, la fatigue et les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment signaler un effet indésirable ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants doivent signaler tout effet indésirable à l'équipe de recherche immédiatement."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier selon les groupes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le groupe de traitement et les caractéristiques des participants."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des essais ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes courants incluent des nausées, des maux de tête et des réactions cutanées."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact des symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact est évalué par des questionnaires et des échelles de mesure standardisées."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut une sélection rigoureuse des participants et une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les mesures de sécurité en essais ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mesures incluent des consentements éclairés, des évaluations de risques et des protocoles stricts."
}
},
{
"@type": "Question",
"name": "Comment informer les participants des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants reçoivent des informations détaillées lors du processus de consentement éclairé."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les participants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les participants doivent suivre les instructions de l'étude et signaler tout problème de santé."
}
},
{
"@type": "Question",
"name": "Comment évaluer la prévention dans les essais ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des études de suivi et des analyses des données de sécurité."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont testés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des médicaments, des thérapies physiques ou des interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Comment sont administrés les traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent être administrés par voie orale, intraveineuse ou topique selon l'étude."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un traitement de contrôle ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement de contrôle est un traitement standard utilisé pour comparer l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des mesures cliniques et des résultats rapportés par les patients."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains essais cliniques testent des traitements personnalisés basés sur le profil génétique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections, des réactions allergiques ou des effets graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications pendant un essai ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par des protocoles d'urgence et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles documentées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, toutes les complications doivent être documentées dans les rapports d'étude."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une évaluation rigoureuse des participants et un suivi constant."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure l'arrêt de l'essai, des soins médicaux supplémentaires ou des poursuites."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les essais ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent l'âge, les antécédents médicaux et les comorbidités."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque sont évalués par des questionnaires et des examens médicaux."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque varient-ils selon les traitements ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les facteurs de risque peuvent varier selon le type de traitement et la population étudiée."
}
},
{
"@type": "Question",
"name": "Comment minimiser les facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "La minimisation passe par une sélection rigoureuse des participants et des protocoles adaptés."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils communiqués aux participants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les participants sont informés des facteurs de risque lors du consentement éclairé."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/03/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Dept. of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: peter.pickkers@radboudumc.nl.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia.
Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, Australia.
Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Herston, Australia.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico,", Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Precision and Translational Medicine, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza University of Rome, Rome, Italy.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. ktodd@uga.edu.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. ratripp@uga.edu.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada di Fiume 447, I-34149 Trieste, Italy.
Publications dans "Expérimentation humaine" :
1 publication dans cette catégorie
Affiliations :
Department of Life Sciences, Cattinara University Hospital, University of Trieste, Strada di Fiume 447, I-34149 Trieste, Italy.
Publications dans "Expérimentation humaine" :
Cancer is a leading cause of morbidity and mortality worldwide with tremendous burden for the individual and the society [...]....
With increasing survival after cancer treatment, there is a need for long-term management of risk factors and chronic medical conditions to realize the full benefit of improvement of outcomes. Hyperte...
A lot of newer anti-cancer therapies have been implicated in the development or worsening of hypertension. We summarize the latest data, explore associations between these therapies and hypertension, ...
Persons newly diagnosed with pancreas cancer and who have survived a previous cancer are often excluded from clinical trials, despite limited evidence about their prognosis. We examined the associatio...
This US population-based cohort study included older adults (aged ≥66 years) diagnosed with pancreas cancer between 2005 and 2015 in the linked Surveillance, Epidemiology, and End Results-Medicare dat...
Of 32,783 patients, 18.7% were previously diagnosed with another cancer. The most common previous cancers included prostate (29.0%), breast (18.9%), or colorectal (9.7%) cancer. More than half of prev...
Given nearly equivalent survival compared to those without previous cancer, cancer survivors newly diagnosed with pancreas cancer should be considered for inclusion in pancreas cancer clinical trials....
We investigated sleep disturbances among cancer survivors compared to similarly aged women without cancer history....
We identified 2067 women with a history of cancer other than breast or non-melanoma skin cancer at enrollment in the Sister Study, a US-wide cohort of women with a family history of breast cancer. Can...
At enrollment, cancer survivors were on average 13.8 years (range=0, 62) from diagnosis. After adjustment for age at enrollment and depression, diabetes, hypertension, and menopausal status prior to t...
Addressing sleep disturbances may improve well-being for cancer survivors....
To explore: 1) the unmet needs of breast cancer patients; 2) the sexual needs experienced by breast cancer survivors; 3) the experiences of cancer patients at the time of relapse, including the biopsy...
Interpretative phenomenological qualitative research by conducting direct in-depth interviews with participants who met the inclusion criteria. Sample analyzed were breast cancer survivors who had exp...
Themes identified for breast cancer patients with unmet needs were i) overcoming health problems in breast cancer survivors; ii) need to access the best health services; iii) women's unmet information...
Health-related problems of breast cancer survivors, such as fatigue and fear of cancer recurrence, can lead them to have trouble with social relationships, question their spirituality, and struggle wi...
This research aims to systematically review a comprehensive sample of websites (English-language) that provide information on nutrition after cancer treatment....
In consultation with cancer survivors and experts, we developed search strings for an internet search (incognito mode in Google Chrome) to be completed in six English-speaking countries (Ireland, the ...
Initially, 720 links were found, with 159 eligible for inclusion. Those eligible for review were charity/support/non-governmental organisation weblinks (49.1%) that originated in the United States (42...
Cancer survivors seeking nutrition information online may encounter difficulty locating advice, and where they do, it is unlikely to contain guidance on implementation into day-to-day life. This is co...
Breast cancer patients commonly present to their OBGYN during the process of diagnosis and treatment of breast cancer both for specific gynecologic needs and for primary care follow up. These patients...
Fear of cancer recurrence is common among survivors of adult-onset cancer and associated with increased distress, functional impairment, and health care utilization. However, little is known about the...
To characterize the prevalence of and risk factors for clinically significant fear of cancer recurrence in adult survivors of childhood cancer....
This cross-sectional investigation included participants recruited from the Childhood Cancer Survivor Study, a retrospective cohort study of long-term childhood cancer survivors treated at 31 institut...
Clinically significant fear of cancer recurrence was assessed via the Fear of Cancer Recurrence Inventory-Short Form. Poisson regression models estimated prevalence ratios (PRs) with 95% CIs adjusted ...
The final sample included 229 adult survivors of childhood cancer (115 female [50.2%]; mean [SD] age, 39.6 [9.9] years; mean [SD] time since diagnosis, 31.7 [8.4] years). Among survivors, 38 (16.6%; 9...
Decades following treatment, one-third of childhood cancer survivors in this study reported elevated fear their cancer will recur or a subsequent malignant neoplasm will develop. Findings suggest that...
Financial burden and distress are high in patients with thyroid cancer. However, little has been done to evaluate potential interventions to mitigate financial toxicity in survivors. This review will ...
Thyroid cancer incidence has nearly tripled in the past decades, and cost of treatment is predicted to rise more than other cancers over the next decade. With mean age of diagnosis at 51 years, most p...
Thyroid cancer survivors have high rates of financial toxicity, and there remains need for longitudinal studies to evaluate how financial burden may change during the treatment process while also asse...
Little is known about cancer survivors' needs in Alaska. To address this knowledge gap, the Alaska Cancer Partnership conducted a needs assessment survey; our objectives were to identify unmet needs o...
Cancer survivors were identified using data from the Alaska Cancer Registry. A random sample of 2,600 individuals was selected to receive the survey, which assessed unmet needs across the following do...
We received 335 survey responses, for a response of 13.7%. Only 29.9% of cancer survivors expressed that all their needs were met. The most highly ranked unmet needs were as follows: help to reduce st...
This assessment provided some of the first information regarding the needs of Alaska's cancer survivors. These results will be used by Alaska Cancer Partnership members across the state to inform heal...